Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remibrutinib phase 3 study in adults with chronic spontaneous urticaria inadequately controlled by H1-antihistamines
2021-000471-37Phase 3Completed
- Sponsor
- Novartis
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic idiopathic urticaria (CIU) comparing Remibrutinib with Placebo (2 arms). Primary endpoints: Absolute change from baseline in UAS7, Absolute change from baseline in ISS7 and 1 more. Started Sep 2021; status: completed.
02
Drugs
remibrutinib
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on 2021-000471-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000471-37.